Skip to content
thestock.space

As of 6 Nov 2026, Aurobindo Pharma trades at 26.1× trailing earnings, below the industry P/E of 28.7×, and the shares are close to their 52-week high. Its ROCE of 14% is the second-lowest among the 7 largest Drug Manufacturers (Specialty & Generic) peers, and sales and net profit grew 11% and 22% a year over 3 years. Its dividend yield is 0.8%, and debt is 0.22× equity. It is a large-cap company with a market cap of ₹1.0 lakh crore, ranked 9th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares rose 55% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Sep 2026.How we calculate this

past year
Open
₹1,784.30
Day high
₹1,805.00
Day low
₹1,776.00
Prev. close
₹1,785.00
Volume
13 L

Health check

3 good · 3 fair
  • ReturnsAhead

    +55.3% over a year, better than 6 of 7 peers.

  • Price tagIn line

    P/E 26.1 vs industry 28.7.

  • GrowthSteady

    Sales +10.7%, profit +22.0% a year over 3 years.

  • ProfitabilityAverage

    ROCE 13.5% vs peer median 17.9%.

  • Balance sheetSolid

    Debt 0.22× equity, interest covered 15.5×, Piotroski 6 of 9.

  • Red flagsNone found

    No warning signs in the headline numbers.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Large cap

₹1.0L Cr, #9 of 154 in its industry by size.

Market sensitivity

Measuring against the NIFTY 50…

Key metrics

Last 12 months to Sep 2026: sales ₹36,913 Cr · profit ₹3,990 Cr
Market cap
₹1.0L Cr
Large cap
P/E
26.1
Industry 28.7
Price to book
2.63
Peers 4.99
Dividend yield
0.78%
ROE
10.7%
Peers 14.7%
ROCE
13.5%
Peers 17.9%
Debt to equity
0.22
Debt ₹8,630 Cr
EPS (TTM)
₹69.05
Face value ₹1
OPM (TTM)
20.7%
Net margin 10.8%
Sales growth
+23.9%
Latest quarter vs a year ago
Profit growth
+33.9%
Latest quarter vs a year ago
Price to sales
2.81
EV/EBITDA 13.6

Strengths and risks

Strengths

  • Quarterly profit up 33.9% on a year ago.
  • Quarterly sales up 23.9% on a year ago.
  • Positive operating cash flow in each of the last 4 years.

No obvious red flags in the headline numbers.

Derived automatically from reported figures. Not a recommendation.

About Aurobindo Pharma

Aurobindo Pharma Limited, a pharmaceutical company, develops, manufactures, and commercializes generic pharmaceuticals in India, the United States, Europe, and internationally. The company manufactures a range of finished formulation products in various forms, such as oral solids, liquids, injectables for generic pharmaceuticals, branded specialty pharmaceuticals, and active pharmaceutical ingredients for CNS, anti-retroviral, cardiovascular, antibiotics,…

Headquarters
Hyderabad
Employees
29,209
Sector
Healthcare
ISIN
INE406A01037
Website
aurobindo.com

Price range

52 weeks

₹1,106.00₹1,805.00

Today

₹1,776.00₹1,805.00
Avg volume (3M)
9.1 L
1-year return
plus 55.3%
From 52-week high
minus 0.3%

Analyst consensus

26 analysts
BuyMean target ₹1,757.15 minus 2.4%

The mean target is below today’s price.

Target range, with today’s price

Low ₹1,270.00High ₹2,000.00

Consensus from Yahoo Finance. Not a recommendation.

Peers · Drug Manufacturers - Specialty & Generic

Compare with peersScreen the whole industry
Company
SUNPHARMASun Pharmaceutical Industries1,860.00plus 1.69%4,46,27640.74.9917.9%13.1%28.2%10.4%10.6%0.87%plus 8.2%
DIVISLABDivi's Laboratories10,320.50plus 1.78%2,73,97793.616.3519.0%16.2%34.9%11.0%12.1%0.30%plus 49.0%
TORNTPHARMTorrent Pharmaceuticals4,750.00plus 0.85%1,80,67580.29.839.1%15.7%33.7%13.3%20.2%0.81%plus 31.7%
LAURUSLABSLaurus Labs2,340.00minus 0.26%1,26,43394.420.8619.5%24.0%30.4%3.8%4.0%0.09%plus 138.6%
ZYDUSLIFEZydus Lifesciences1,197.90plus 0.41%1,19,49128.64.2919.0%14.7%26.2%16.5%37.0%0.08%plus 22.8%
DRREDDYDr. Reddy's Laboratories1,373.00plus 0.51%1,14,46240.92.9614.2%7.3%15.9%11.0%−1.7%0.59%plus 13.8%
CIPLACipla1,411.00plus 0.49%1,13,99339.43.2214.9%8.3%17.3%7.2%11.5%0.93%minus 6.6%
AUROPHARMAAurobindo Pharma1,800.00plus 0.84%1,03,56826.12.6313.5%10.7%20.6%10.7%22.0%0.78%plus 55.3%
Median of 7 peers–0.51%1,26,43340.94.9917.9%14.7%28.2%11.0%11.5%0.59%22.8%

Quarterly results

Consolidated, ₹ crore
SalesSelect a row below to chart it
₹ CrJun 25Dec 25Mar 26Jun 26Sep 26
7,7928,6058,7529,10610,227
6,1886,8316,9517,2258,072
1,6031,7731,8011,8812,156
20.6%20.6%20.6%20.7%21.1%
10718866.5263165
97.892.898.2102102
406465479487531
–−65.3–−40.2–
1,2071,3391,2911,5151,688
31.7%32.0%28.7%31.9%33.4%
8259109211,0331,126
14.2015.6715.8617.8619.57

Sep 25 not reported by the data source.

Profit & loss

Yearly, ₹ crore
Sales CAGR 3Y
+10.7%
Profit CAGR 3Y
+22.0%
EPS CAGR 3Y
+22.4%
ROE
10.7%
Net profitSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
24,61728,70531,37833,385
–+16.6%+9.3%+6.4%
20,83522,74124,73926,431
3,7825,9636,6396,954
15.4%20.8%21.2%20.8%
215494551452
129268440352
1,2451,5221,5911,761
−10.7−288−92−180
2,6134,3805,0665,112
26.2%27.6%31.2%31.5%
1,9283,1733,4863,505
–+64.6%+9.9%+0.5%
32.9054.1659.8160.34

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore
Total assetsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
58.658.658.158.1
26,78129,78432,59537,833
5,2866,6488,2638,073
7,7648,5818,86912,538
39,89045,07249,78558,502
12,80414,41215,63417,609
4,8082,8663,4453,279
228152118106
6,2246,3258,19910,579
15,82621,31722,39026,929
39,89045,07249,78558,502

Cash flow

Yearly, ₹ crore
Cash from operationsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
2,3872,4353,9255,526
−3,978−4,256−1,876−3,459
1,814800120−1,269
223−1,0212,169799
−2,720−3,562−2,520−3,105
−334−1,1271,4052,422
−440−264−1−232

Shareholding pattern

Source: NSE filings
51.9%
promoters
  • Promoters51.88%
  • Public48.12%
  • As of 30 Sep 2026
QuarterSplitPromotersPublicPromoter change
30 Sep 202651.88%48.12%0.00
30 Jun 202651.88%48.12%plus 0.06
31 Mar 202651.82%48.18%0.00
31 Dec 202551.82%48.18%0.00
30 Sep 202551.82%48.18%–

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you